Lagos PSN raises alarm over pharmacist shortage, demands

Nigeria's largest commercial hub is confronting a public health crisis that few investors and policymakers are watching closely: a dangerous depletion of qualified pharmacists in Lagos State's Ministry of Health. The Pharmaceutical Society of Nigeria (PSN) Lagos State Branch has sounded an urgent alarm, warning that staffing collapse in the state's drug control directorate is already weakening pharmaceutical regulation and creating a vacuum that counterfeit and substandard drugs could exploit.

## What is driving the pharmacist shortage in Lagos?

The exodus reflects a combination of factors: brain drain to international markets (UK, USA, Canada offer 3–5x higher salaries), inadequate government remuneration, poor working conditions, and limited career progression within state health ministries. Lagos, with over 15 million residents and Africa's largest pharmaceutical supply chain, is particularly vulnerable. The state's drug control directorate—responsible for inspecting facilities, testing medicines, and preventing fake drugs—operates with skeleton staff. PSN leadership has called on Governor Babajide Sanwo-Olu to urgently strengthen the directorate through competitive pay, recruitment, and retention schemes.

The timing is critical. Nigeria loses an estimated $5 billion annually to counterfeit pharmaceuticals, according to WHO estimates. Lagos, as the gateway for 80% of Nigeria's drug imports and home to pharmaceutical manufacturing hubs in Ikeja and Apapa, faces outsized risk if regulatory capacity continues eroding.

## How does this threaten investor confidence in Nigeria's pharma sector?

The shortage directly undermines one of Nigeria's most promising sectors. The domestic pharmaceutical market is worth $4.2 billion and growing at 8–10% annually, yet regulatory weakness drives multinational and local manufacturers toward exporting rather than expanding locally. Foreign investors in drug manufacturing and distribution require assurance that government agencies can enforce quality standards and combat counterfeiting—exactly what PSN says is now compromised in Lagos.

Weak oversight also creates liability. When substandard medicines reach patients, reputational damage spreads to legitimate manufacturers and distributors. Health crises—like the 2018 counterfeit drug scandal that killed dozens—trigger international scrutiny and market shutdowns.

## Why hasn't government responded?

Budget constraints explain part of the delay. States rely on federal allocations that often arrive late or reduced. But PSN's demands go beyond salary: they're calling for structural reform—establishing the directorate as an autonomous agency with dedicated funding, modern testing laboratories, and regulatory authority independent of day-to-day ministry operations. This mirrors successful models in Ghana (Food & Drugs Authority) and South Africa (SAHPRA).

Governor Sanwo-Olu's administration has invested in health infrastructure (new hospitals, diagnostic centers) but pharmaceutical regulation remains underfunded relative to its economic importance. A reinforced directorate would cost ₦2–5 billion annually—a fraction of what counterfeiting costs the state economy in lost tax revenue, health spending, and investor confidence.

## What's at stake?

If the shortage worsens, expect: (1) surge in fake drug prevalence; (2) delayed market entry for legitimate new drugs; (3) manufacturing and distribution firms relocating to better-regulated states or countries; (4) patient harm and erosion of public trust in medicines. Conversely, swift intervention—hiring 50–100 pharmacists, upgrading labs, and ring-fencing the directorate's budget—could position Lagos as West Africa's pharmaceutical hub and unlock $2+ billion in manufacturing investment over five years.

---

#